Kapsia Eleni, Marinaki Smaragdi, Michelakis Ioannis, Liapis George, Sfikakis Petros P, Boletis John, Tektonidou Maria G
Department of Nephrology and Renal Transplantation, Laiko Hospital, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.
Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece.
J Clin Med. 2022 Aug 26;11(17):5017. doi: 10.3390/jcm11175017.
To define predictors of response, time to response, flares, and long-term renal outcome in an inception cohort of proliferative lupus nephritis (PLN). We included 100 patients (80% female; mean age 31 ± 13 years) with biopsy-proven PLN (III, IV, III/IV + V). Clinical, laboratory, histological and therapeutical parameters were recorded at baseline, 6, 9, 12, 18, 24, 36, 72 months, time of flare, and last follow-up visit. Logistic and Cox-regression models were applied. After induction treatment (69% received cyclophosphamide (CYC) and 27% mycophenolic acid (MPA)), partial (PR) or complete (CR) response was achieved in 59% (26% CR, 33% PR) and 67% (43% CR, 24% PR) of patients at 3 and 6 months, respectively; median time to PR was 3 months (IQR 5) and median time to CR was 6 months (IQR 9). Baseline proteinuria <1.5 g/day correlated with a shorter time to CR (HR 1.77) and with CR at 3, 6, and 9 months (OR 9.4, OR 5.3 and OR 3.7, respectively). During 100-month median follow-up, 33% of patients had ≥1 renal flares (median time: 38 months). Proteinuria >0.8 g/day at 12 months was associated with a higher risk of flares (OR 4.12), while MPA and mixed classes with lower risk (OR 0.14 and OR 0.13, respectively). Baseline proteinuria >2 g/day and 12-month proteinuria >0.8 g/day correlated with a shorter time to flare (HR 2.56 and HR 2.57, respectively). At the end of follow-up, 10% developed stage 3-4 chronic kidney disease (CKD), and 12% end-stage renal disease (ESRD). Twelve-month proteinuria >0.8 g/day (OR 10.8) and interstitial fibrosis/tubular atrophy >25% (OR 7.7) predicted CKD or ESRD at last visit. Baseline proteinuria <1.5 g/day predicted time to CR. Twelve-month proteinuria >0.8 g/day correlated with flares (ever) and time to flare and, along with baseline interstitial fibrosis/tubular atrophy >25%, predicted CKD or ESRD at the last visit.
为了确定增殖性狼疮性肾炎(PLN)起始队列中反应的预测因素、反应时间、病情复发及长期肾脏结局。我们纳入了100例经活检证实为PLN(III、IV、III/IV + V型)的患者(80%为女性;平均年龄31±13岁)。在基线、6、9、12、18、24、36、72个月、病情复发时及最后一次随访时记录临床、实验室、组织学和治疗参数。应用逻辑回归和Cox回归模型。诱导治疗后(69%接受环磷酰胺(CYC),27%接受霉酚酸(MPA)),分别有59%(26%完全缓解(CR),33%部分缓解(PR))和67%(43% CR,24% PR)的患者在3个月和6个月时达到PR或CR;达到PR的中位时间为3个月(四分位间距5),达到CR的中位时间为6个月(四分位间距9)。基线蛋白尿<1.5 g/天与达到CR的时间较短相关(风险比1.77),并与3、6和9个月时的CR相关(优势比分别为9.4、5.3和3.7)。在100个月的中位随访期间,33%的患者发生≥1次肾脏病情复发(中位时间:38个月)。12个月时蛋白尿>0.8 g/天与病情复发风险较高相关(优势比4.12),而MPA及混合类别风险较低(优势比分别为0.14和0.13)。基线蛋白尿>2 g/天和12个月时蛋白尿>0.8 g/天与病情复发时间较短相关(风险比分别为2.56和2.57)。随访结束时,10%的患者发展为3 - 4期慢性肾脏病(CKD),12%发展为终末期肾病(ESRD)。12个月时蛋白尿>0.8 g/天(优势比10.8)和间质纤维化/肾小管萎缩>25%(优势比7.7)预测最后一次随访时的CKD或ESRD。基线蛋白尿<1.5 g/天预测达到CR的时间。12个月时蛋白尿>0.8 g/天与(既往)病情复发及病情复发时间相关,并且与基线间质纤维化/肾小管萎缩>25%一起预测最后一次随访时的CKD或ESRD。